GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Correction protection. 3 best Street ideas on week Saturday, 25 Apr 2015 | 7:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    CNBC Pro highlights the three best strategy notes that came across our desk this week.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • AstraZeneca eyes new cancer deals after Nexium hit Friday, 24 Apr 2015 | 3:35 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca has sharpened its focus on cancer drugs as it looks beyond a hit to sales from the launch of cheap copies of its acid pill Nexium.

  • LONDON, April 24- AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market. AstraZeneca will get an upfront payment of $450 million from Celgene, while Innate will receive an initial $250 million from...

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • April 23- Investment bank and asset manager Lazard Ltd reported a better-than-expected quarterly profit as a jump in corporate dealmaking boosted its M&A advisory fees. M&A and other advisory fees for Lazard, the sole adviser to H.J. Some of the other ongoing big deals that Lazard is part of include AT&T Inc's $67.1 billion bid for DirecTV and Pfizer Inc's $17...

  • Bang for your buck: Where earnings surprises are Thursday, 23 Apr 2015 | 8:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Three sectors are seeing the biggest rallies following earnings reports. Where investors should place future bets.

  • April 23- Investment bank and asset manager Lazard Ltd reported a better-than-expected quarterly profit as a jump in corporate dealmaking boosted its M&A advisory fees. M&A and other advisory fees for Lazard, the sole adviser for H.J. The other ongoing big deals that Lazard is part of include AT&T Inc's $67.1 billion bid for DIRECTV and Pfizer Inc's $17 billion...

  • LONDON, April 22- Swiss drugmaker Roche has "renewed confidence" that drugs targeting potentially brain-destroying plaque can fight Alzheimer's disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O'Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer's drugs, both of...

  • HAVANA, April 21- A U.S. cancer research center and a software company reached agreements with Cuban partners during a two-day trade mission to Cuba led by New York Governor Andrew Cuomo in the first trip of its kind since the rapprochement between the longtime adversaries. The Roswell Park Cancer Institute of Buffalo, New York, on Tuesday signed an agreement...

  • HAVANA, April 21- A U.S. cancer research center and a software company reached agreements with Cuban partners during a two-day trade mission to Cuba led by New York Governor Andrew Cuomo in the first trip of its kind since the rapprochement between the longtime adversaries. The Roswell Park Cancer Center of Buffalo, New York, on Tuesday signed an agreement with...

  • LONDON, April 21- AstraZeneca's recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday. AstraZeneca has flagged olaparib as a potential $2- billion- a-year seller, based on ongoing Phase III studies in ovarian, breast, gastric and pancreatic cancers.

  • *Global nutraceutical market seen at $280 bln by 2018. LONDON, April 21- A boom in "nutraceuticals"- food and drinks with potential health benefits- is paving the way for a rush of deals, as food and drug companies compete to dominate a market expected to be worth $280 billion by 2018.. "The space is ripe for M&A and I think you are going to see more," added Jeremy Johnson,...

  • HAVANA, April 20- New York Governor Andrew Cuomo met senior Cuban officials in Havana on Monday as the head of a high-powered business delegation looking to take advantage of President Barack Obama's easing of restrictions with the Communist-led island. Cuomo, a Democrat, is the first governor to visit Cuba since a December announcement by Obama and Cuban...

  • April 17- Pfizer Inc was cleared of liability on Friday in the first lawsuit to go to trial of more than 1,000 filed across the United States alleging that its antidepressant Zoloft can cause birth defects, a company spokeswoman said. Plaintiff Kristyn Pesante claimed that Pfizer failed to warn that using Zoloft during pregnancy could cause birth defects, and...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Big pharma M&A may keep booming, CEOs say Thursday, 16 Apr 2015 | 3:44 PM ET
    Generic copies of Merck & Co.'s cholesterol pill Zocor and Pfizer Inc.'s Zoloft antidepressant.

    For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...